Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.52 |
| ▸ | GBA1 | P04062 | 2/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | DRD1 | P21728 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | HRH1 | P35367 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | SCN1A | P35498 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3193207 | 0.80 | GBA1 (0.50) | TAAR1GBA1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17226279 | 0.80 | KDM4E (0.42) | GBA1MCHR1HIF1A | |
| SCHEMBL16327094 | 0.78 | NPSR1 (0.41) | TAAR1CHRNA7HRH3HRH1KCNH2 | |
| SCHEMBL31729646 | 0.78 | GBA1 (0.52) | GBA1HRH3LMNANFKB1ADRA2B | |
| SCHEMBL3231706 | 0.78 | GBA1 (0.52) | GBA1HRH3LMNANFKB1ADRA2B | |
| SCHEMBL30189191 | 0.78 | GBA1 (0.41) | TAAR1GBA1CHRM2CHRM1DRD1 | |
| SCHEMBL21911797 | 0.78 | GBA1 (0.41) | TAAR1GBA1CHRM2CHRM1DRD1 | |
| SCHEMBL17226273 | 0.77 | TSHR (0.40) | GBA1MCHR1HIF1A | |
| SCHEMBL19566680 | 0.77 | CHRNA7 (0.38) | TAAR1CHRNA7HRH3HRH1CYP2D6 | |
| SCHEMBL9054449 | 0.77 | CHRNA7 (0.42) | TAAR1CHRNA7HRH3HRH1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-11931363-B2 | Triazolopyrimidine compounds and uses thereof | NOVARTIS AG (CH) | 2024-03-19 | — | — | US | disclosed |
| US-20230033320-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH (CN) | 2023-02-02 | — | — | US | disclosed |
| US-11207325-B2 | Triazolopyrimidine compounds and uses thereof | NOVARTIS AG (CH) | 2021-12-28 | — | — | US | disclosed |
| US-20200323859-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) | 2020-10-15 | — | — | US | disclosed |
| US-10676479-B2 | Imidazolepyridine compounds and uses thereof | NOVARTIS AG (CH) | 2020-06-09 | — | — | US | disclosed |
| US-20190233426-A1 | IMIDAZOLEPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-08-01 | — | — | US | disclosed |
| US-20190142837-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-05-16 | — | — | US | disclosed |
| US-9580437-B2 | Triazolopyrimidine compounds and uses thereof | NOVARTIS AG (CH) | 2017-02-28 | — | — | US | disclosed |
| US-9580437-B2 | Triazolopyrimidine compounds and uses thereof | NOVARTIS AG (CH) | 2017-02-28 | — | — | US | disclosed |
| US-9580437-B2 | Triazolopyrimidine compounds and uses thereof | NOVARTIS AG (CH) | 2017-02-28 | — | — | US | disclosed |
| WO-2016103155-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2016-06-30 | — | — | WO | disclosed |
| US-20160176882-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2016-06-23 | — | — | US | disclosed |
| US-20160176882-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2016-06-23 | — | — | US | disclosed |
| US-20160176882-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2016-06-23 | — | — | US | disclosed |
| US-7879808-B2 | potent activity against resistant pneumococci; for treating domestic fowl | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| EP-2151447-A1 | LINCOMYCIN DERIVATIVES AND ANTIBACTERIAL AGENTS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Meiji Seika Kaisha Ltd. (JP) | 2010-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11931363-B2 | Triazolopyrimidine compounds and uses thereof | EZH2, DOT1L, EED | TAAR1 3458/4885GBA1 3936/4885CHRNA7 3789/4885 |
| US-11207325-B2 | Triazolopyrimidine compounds and uses thereof | EZH2, DOT1L, EED | TAAR1 3458/4885GBA1 3936/4885CHRNA7 3789/4885 |
| US-20190233426-A1 | IMIDAZOLEPYRIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, BMI1 | TAAR1 3168/4885GBA1 3860/4885CHRNA7 1205/4885 |
| US-20200323859-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | TAAR1 3458/4885GBA1 3936/4885CHRNA7 3789/4885 |
| US-10676479-B2 | Imidazolepyridine compounds and uses thereof | EZH2, DOT1L, BMI1 | TAAR1 3168/4885GBA1 3860/4885CHRNA7 1205/4885 |
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | LAS1L, LCLAT1, LYPLA1 | TAAR1 4340/4885GBA1 248/4885CHRNA7 4720/4885 |
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | TAAR1 3458/4885GBA1 3936/4885CHRNA7 3789/4885 |
| US-20160176882-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | TAAR1 3458/4885GBA1 3936/4885CHRNA7 3789/4885 |
| US-20190142837-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | TAAR1 3458/4885GBA1 3936/4885CHRNA7 3789/4885 |
| US-20230033320-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | TAAR1 3458/4885GBA1 3936/4885CHRNA7 3789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.